JP7234349B2 - メリチンベースのアポトシース促進ペプチドペプチドでm2様腫瘍関連マクロファージの標的化 - Google Patents
メリチンベースのアポトシース促進ペプチドペプチドでm2様腫瘍関連マクロファージの標的化 Download PDFInfo
- Publication number
- JP7234349B2 JP7234349B2 JP2021512351A JP2021512351A JP7234349B2 JP 7234349 B2 JP7234349 B2 JP 7234349B2 JP 2021512351 A JP2021512351 A JP 2021512351A JP 2021512351 A JP2021512351 A JP 2021512351A JP 7234349 B2 JP7234349 B2 JP 7234349B2
- Authority
- JP
- Japan
- Prior art keywords
- mel
- dkla
- tumor
- succinimidyl
- melittin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Description
rbodiimide)、SATA、(succinimidyl acetylthioacetate)、スルホ-SMCC(sulfosuccinimidyl-4-(NDmaleimidomethyl)cyclohexane-1-carboxylate)、DMA(dimethyl adipimidate・2HCl)、DMP(dimethylpimelimidate・2HCl)、DMS(dimethyl Suberimidate・2HCl)、DTBP(dimethyl 3,3’-dithiobispropionimidate・2HCl)、スルホ-SIAB(sulfosuccinimidyl(4-iodoacetyl)aminobenzoate )、SIAB(succinimidyl (4-iodoacetyl)aminobenzoate)、SBAP(succinimidyl 3-(bromoacetamido)propionate)、SIA(succinimidyl iodoacetate)、SM(PEG)n(succinimidyl-([N- maleimidopropionamido]-#ethyleneglycol ester、前記n=2、4、6、8、12、または24)、SMCC(succinimidyl-4-(N-Dmaleimidomethyl)cyclohexane-1-carboxylate)、LCSMCC(succinimidyl 4-(N-maleim idomethyl)cyclohexane-1-carboxy-(6-amidocaproate))、スルホ-EMCS(N-εester)、EMCS(N-εスルホ-GMBS(N-γester)、GMBS(N-γester)、スルホ-KMUS(N-κester)、スルホ-MBS(m- maleimidobenzoyl- Nhydroxysulfosuccinimide ester)、MBS(m- maleimidobe nzoyl-N-hydroxysuccinimide ester)、スルホ-SMPB(sulfosuccinimidyl 4-(pmaleimidophenyl)butyrate)、SMPB(succinimidyl 4-(pmaleimidophenyl)butyrate)、AMAS(N-α-maleimidoacet-oxysuccinimide ester)、BMPS(N-β- maleimidopropyloxysuccinimide ester)、SMPH(succinimidyl 6-[(β-maleimidopropionamido )hexanoate])、PEG12-SPDP(2-pyridyldithiol-tetraoxaoctatriacontane-N-hydroxysuccinimide)、PEG4-SPDP、スルホ-LCSPDP(sulfosuccinimidyl 6-[3’-(2-pyridyldithio)propionamido]hexanoate)、SPDP(succinimidyl 3-(2-pyridyldithio)propionate)、LC-SPDP(succinimidyl 6-[3’-(2-pyridyldithio)propionamido]hexanoate)、SMPT(4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio)toluene)、DSS(disuccinimidyl suberate)、BS(PEG)5(bis(succinimidyl)penta(ethylene glycol))、BS(PEG)9(bis(succinimidyl)nona(ethylene glycol))、BS3(bis[sulfosuccinimidyl]suberate)、BSOCOES(bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone)、PDPH(3-(2-pyridyldithio)propionyl hydrazide)、DSG(disuccinimidy l glutarate )、DSP(dithiobis[succinimidyl propionate])、BM(PEG)n(1,8-bismaleimido- ethyleneglycolで、n=2または3)、BMB(1,4-bismaleimidobutane)、BMDB(1,4-bismaleimidyl-2,3-dihydroxybutane)、BMH(bismaleimidohexane)、BMOE(bismaleimidoethane)、DTME(dithiobismaleimidoethane)、TMEA(tris(2-maleimidoethyl)amine)、DSS(disuccinimidyl suberate )、DST(disuccinimidyl tartarate)、DTSSP(3、3’-dithiobis[sulfosuccinimidylpropionate])、EGS(ethylene glycol bis[succinimidylsuccinate])、スルホ-EGS(ethylene glycol bis[sulfosuccinimidylsuccinate])とTSAT(tris-succinimidyl aminot riacetate)、DFDNB(1,5-difluoro-2,4-dinitrobenzene)及びこれらの組み合わせであることができるが、これに限定されるものではない。
Claims (9)
- メリチン(Melittin)が抗がん剤と結合された、メリチン-抗がん剤結合体であって、
前記抗がん剤が、ドキソルビシン(Doxorubicin)、メトトレキサート(Methotrexate)、エンチノスタット(Entinostat)、クラドリビン(Cladribine)、プララトレキセート(Pralatrexate)、ロルラチニブ(Lorlatinib)、メイタンシンDM1(Maytansine DM1)、メイタンシンDM3(Maytansine DM3)、メイタンシンDM4(Maytansine DM4)およびこれらの組み合わせからなる群から選択され、
前記結合体が、M2型腫瘍関連マクロファージを標的とするものであり、抗がん剤に比べて抗がん活性が向上されたものである、メリチン-抗がん剤結合体。 - 前記メリチンおよび抗がん剤は、化学的リンカーまたは直接連携によって連結されたものであることを特徴とする請求項1に記載のメリチン-抗がん剤結合体。
- 前記化学的リンカーは、メリチンおよび抗がん剤上のアミン基(amine)、カルボキシ基(carboxyl)またはスルフヒドリル基(sulfhydryl)を介して結合するものであることを特徴とする請求項2に記載のメリチン-抗がん剤結合体。
- 前記化学的リンカーは、両末端にカルボジイミド基(carbodiimide)、N-ヒドロキシコハク酸イミドエステル(N -hydroxysuccinimide ester;NHS ester)、イミドエステル(imidoester)、ペンタフルオロフェニルエステル(pentafluorophenyl ester)、ヒドロキシメチルホスフィン(hydroxymethyl phosphine)、マレイミド(maleimide)、ハロアセチル(haloacetyl)、ピリジルジスルフィド(pyridyldisulfide)、チオスルホネート(thiosulfonate)、ビニールスルホン(vinylsulfone)およびこれらの組み合わせから選択される官能基を含むことを特徴とする請求項2に記載のメリチン-抗がん剤結合体。
- 前記化学的リンカーは、EDC(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide)、DCC(N、N’- dicyclohexylcarbodiimide)、SATA(succinimidyl acetylthioacetate)、スルホン-SMCC(sulfosuccinimidyl-4-(NDmaleimidomethyl)cyclohexane-1-carboxylate)、DMA(dimethyl adipimidate・2HCl)、DMP(dimethylpimelimidate・2HCl)、DMS(dimethyl Suberimidate・2HCl)、DTBP(dimethyl 3,3’- dithiobispropionimidate・2HCl)、スルホ-SIAB(sulfosuccinimidyl(4-iodoacetyl)aminobenzoate)、SIAB(succinimidyl(4-iodoacetyl)aminobenzoate)、SBAP(succinimidyl 3-(bromoacetamido)propionate)、SIA(succinimidyl iodoacetate)、SM(PEG)n(succinimidyl -([N- maleimid opropionamido]-#ethyleneglycol ester、前記n=2、4、6、8、12、または24)、SMCC(succinimidyl-4-(N-Dmaleimidomethyl)cyclohexane-1-carboxylate)、LCSMCC(succinimidyl-4-(N- maleimidomethyl)cyclohexane-1-carboxy-(6 amidocaproate))、スルホ-EMCS(N-εester)、EMCS(N-εスルホ-GMBS(N-γester)、GMBS(N-γester)、スルホ-KMUS(N-κester)、スルホ-MBS(m- maleimidobenzoyl-Nhydroxysulfosuccinimide ester)、MBS(m-maleimidobenzoyl-N-hydroxysuccinimide ester)、スルホ-SMPB(sulfosuccinimidyl-4-(pmaleimidophenyl)butyrate)、SMPB(succinimidyl-4-(pmaleimidophenyl)butyrate)、AMAS(N-α-maleimidoacet-oxysuccinimide ester)、BMPS(N-β-maleimidopropyloxysuccinimide ester)、SMPH(succinimidyl 6-[(β-maleimidopropionamido)hexanoate])、PEG12-SPDP(2-pyridyldithiol-tetraoxaoctatriacontane-N-hydroxysuccinimide)、PEG4-SPDP、スルホ-LCSPDP(sulfosuccinimidyl 6-[3’-(2-pyridyldithio)propionamido]hexanoate)、SPDP(succinimidyl 3-(2-pyridyldithio)propionate)、LC-SPDP(succinimidyl 6-[3’-(2-pyridyldithio)propionamido]hexanoate)、SMPT(4-succinimidyloxycarbonyl-alpha-methyl-alpha(2-pyridyldithio)toluene)、DSS(disuccinimidyl suberate)、BS(PEG)5(bis(succinimidyl)penta(ethylene glycol))、BS(PEG)9(bis(succinimidyl)nona(ethylene glycol))、BS3(bis[sulfosuccinimidyl]suberate)、BSOCOES(bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone)、PDPH(3-(2-pyridyldithio)propionyl hydrazide)、DSG(disuccinimi dyl glutarate)、DSP(dithiobis[succinimidyl propionate])、BM(PEG)n(1,8-bismaleimido-ethyleneglycol、n=2または3)、BMB(1,4-bismaleimidobutane)、BMDB(1,4-bismaleimidyl-2,3-dihydroxybutane)、BMH(bismaleimidohexane)、BMOE(bismaleimidoethane)、DTME(dithiobismaleimidoethane)、TMEA(tris(2-maleimidoethyl)amine)、DSS(disuccinimidyl suberate)、DST(disuccinimidyl tartarate)、DTSSP(3、3’-dithiobis[sulfosuccinimidylpropionate])、EGS(ethylene glycol bis[succinimidylsuccinate])、スルホ-EGS(ethylene glycol bis[sulfosuccinimidylsuccinate])とTSAT(tris-succinimidyl aminot riacetate)、DFDNB(1,5-difluoro-2、4-dinitrobenzene)およびこれらの組み合わせから選択されるものであることを特徴とする請求項2に記載のメリチン-抗がん剤結合体。
- 請求項1~5のいずれか一項に記載の結合体を含む、腫瘍関連マクロファージ媒介疾患の予防または治療用薬学的組成物。
- 前記疾患は、肺癌、転移癌、乳がんであることを特徴とする請求項6に記載の薬学的組成物。
- 前記疾患は、ルイス肺癌または炎症性疾患であることを特徴とする請求項6に記載の薬学的組成物。
- 前記組成物は、M2型腫瘍関連マクロファージの除去によるがんの成長および転移の予防または治療用薬学的組成物であることを特徴とする請求項6に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0051800 | 2018-05-04 | ||
KR20180051800 | 2018-05-04 | ||
PCT/KR2019/005438 WO2019212324A1 (ko) | 2018-05-04 | 2019-05-07 | 멜리틴-기반 세포사멸 유발 펩타이드로 m2 유사 종앙관련 대식세포의 표적화 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021526548A JP2021526548A (ja) | 2021-10-07 |
JP2021526548A5 JP2021526548A5 (ja) | 2021-11-18 |
JP7234349B2 true JP7234349B2 (ja) | 2023-03-07 |
Family
ID=68386643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021512351A Active JP7234349B2 (ja) | 2018-05-04 | 2019-05-07 | メリチンベースのアポトシース促進ペプチドペプチドでm2様腫瘍関連マクロファージの標的化 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11484601B2 (ja) |
EP (1) | EP3789041A4 (ja) |
JP (1) | JP7234349B2 (ja) |
KR (1) | KR102250412B1 (ja) |
CN (1) | CN112533640A (ja) |
AU (1) | AU2019264092B2 (ja) |
CA (1) | CA3099434C (ja) |
WO (1) | WO2019212324A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240009269A1 (en) * | 2020-11-20 | 2024-01-11 | The Johns Hopkins University | Membrane-active peptides and methods for reversible blood- brain barrier opening |
US20220354957A1 (en) * | 2021-05-07 | 2022-11-10 | Twinpig Biolab, Inc. | Peptides targeting macrophages, and conjugates, compositions, and uses thereof |
CN113336828B (zh) * | 2021-06-30 | 2022-03-25 | 中国海洋大学 | 抗菌肽yhx-3及其组合物和应用 |
CN114437193A (zh) * | 2022-01-29 | 2022-05-06 | 陕西未来多肽生物科技有限公司 | 一种金-蜂毒肽纳米杂化物及其应用 |
KR20230144960A (ko) * | 2022-04-07 | 2023-10-17 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
WO2023204329A1 (ko) * | 2022-04-22 | 2023-10-26 | 트윈피그바이오랩(주) | 신규 펩타이드 기반 면역항암제 |
CN116589555B (zh) * | 2023-03-31 | 2024-02-06 | 广东医科大学 | 一种细胞穿梭肽及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543111A (ja) | 1999-05-04 | 2002-12-17 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 |
CN1572797A (zh) | 1993-09-08 | 2005-02-02 | 拉卓拉药物公司 | 化学上定义的非聚合价平台分子和其偶联物 |
US20050196383A1 (en) | 2003-11-05 | 2005-09-08 | Zurbriggen Rinaldo E. | Compositions and methods for the potentiation of immune responses against target antigens |
CN106795205A (zh) | 2014-09-04 | 2017-05-31 | 迪沃势股份有限公司 | 新细胞膜穿透肽及其作为生物活性物质传递体的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
KR20110117789A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 함유하는 동맥경화 치료용 조성물 |
KR20110117788A (ko) | 2010-04-22 | 2011-10-28 | 대한민국(농촌진흥청장) | 멜리틴을 포함하는 섬유아세포-유사-활막세포의 활성을 억제하는 조성물 |
KR101935095B1 (ko) * | 2015-07-31 | 2019-01-04 | 이화여자대학교 산학협력단 | 신규한 세포투과성 펩타이드 |
CN106699896B (zh) * | 2016-12-05 | 2020-06-05 | 华中科技大学同济医学院附属协和医院 | 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用 |
KR102073273B1 (ko) | 2017-08-23 | 2020-03-02 | (주) 레느스랩 | 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물 |
-
2019
- 2019-05-07 JP JP2021512351A patent/JP7234349B2/ja active Active
- 2019-05-07 AU AU2019264092A patent/AU2019264092B2/en active Active
- 2019-05-07 US US17/052,943 patent/US11484601B2/en active Active
- 2019-05-07 CN CN201980030270.8A patent/CN112533640A/zh active Pending
- 2019-05-07 CA CA3099434A patent/CA3099434C/en active Active
- 2019-05-07 EP EP19796650.0A patent/EP3789041A4/en active Pending
- 2019-05-07 WO PCT/KR2019/005438 patent/WO2019212324A1/ko active Application Filing
- 2019-05-07 KR KR1020190053334A patent/KR102250412B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1572797A (zh) | 1993-09-08 | 2005-02-02 | 拉卓拉药物公司 | 化学上定义的非聚合价平台分子和其偶联物 |
JP2002543111A (ja) | 1999-05-04 | 2002-12-17 | バイオテック・オーストラリア・ピーティーワイ・リミテッド | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 |
US20050196383A1 (en) | 2003-11-05 | 2005-09-08 | Zurbriggen Rinaldo E. | Compositions and methods for the potentiation of immune responses against target antigens |
CN106795205A (zh) | 2014-09-04 | 2017-05-31 | 迪沃势股份有限公司 | 新细胞膜穿透肽及其作为生物活性物质传递体的用途 |
Non-Patent Citations (4)
Title |
---|
Cancer Letters,2017年,Vol.402,p.16-31 |
J. Immunol.,2018年05月01日,Vol.200 (1 Supplement), 56.22,p.1 |
Journal of the American Chemical Society,1954年,Vol.76, No.23,p.6192-6193 |
メリチン,日化辞,番号J11.783H,1961年,p.1 |
Also Published As
Publication number | Publication date |
---|---|
EP3789041A4 (en) | 2022-07-13 |
CN112533640A (zh) | 2021-03-19 |
AU2019264092B2 (en) | 2024-02-15 |
CA3099434A1 (en) | 2019-11-04 |
WO2019212324A1 (ko) | 2019-11-07 |
KR20190127609A (ko) | 2019-11-13 |
AU2019264092A1 (en) | 2020-12-24 |
KR102250412B1 (ko) | 2021-05-17 |
US11484601B2 (en) | 2022-11-01 |
JP2021526548A (ja) | 2021-10-07 |
CA3099434C (en) | 2023-09-05 |
EP3789041A1 (en) | 2021-03-10 |
AU2019264092A8 (en) | 2021-01-07 |
US20210244823A1 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7234349B2 (ja) | メリチンベースのアポトシース促進ペプチドペプチドでm2様腫瘍関連マクロファージの標的化 | |
Oršolić | Bee venom in cancer therapy | |
Kularatne et al. | A CXCR4‐Targeted Site‐Specific Antibody–Drug Conjugate | |
JP6113850B2 (ja) | がん性組織の治療およびがん性腫瘍の再発および転移を予防するための医薬組成物の調製のためのヘモグロビン系酸素運搬体の使用方法 | |
US10233221B2 (en) | Peptide having eight amino acid sequences derived from cage and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug-resistant cancer cells | |
JP2021506849A (ja) | 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法 | |
US20160158374A1 (en) | Cell-penetrating peptide and conjugate comprising same | |
CN105916882A (zh) | 作为用于靶向癌症治疗的细胞毒性药物递送系统的抗-ron单克隆抗体 | |
JP2021527664A (ja) | 合成ペプチドsp2及びその用途 | |
AU2018320102A1 (en) | Composition including melittin for removing M2-type tumor-associated macrophage | |
JP2020501513A (ja) | 治療用多標的コンストラクトおよびその使用 | |
JP7085712B2 (ja) | Vdac1由来ペプチドの類似体 | |
WO2021054448A1 (ja) | ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物 | |
KR102400031B1 (ko) | 항종양 면역 상승효과를 나타내는 종양세포 특이적 자가조립 나노입자 | |
US11712466B2 (en) | Vaccine composition | |
US11179438B1 (en) | Chicken cathelicidins as a cancer therapy | |
US20240156971A1 (en) | Methods and sortilin binding conjugate compounds for targeting cancer stem cells | |
JPWO2019138944A1 (ja) | 細胞殺傷剤 | |
US20220354957A1 (en) | Peptides targeting macrophages, and conjugates, compositions, and uses thereof | |
US20230113262A1 (en) | Peptide for cancer immunotherapy rupturing tumor-derived vesicle and use thereof | |
KR20220152383A (ko) | 대식세포를 표적으로 하는 펩타이드, 컨쥬게이트, 조성물 및 그의 용도 | |
US20210139608A1 (en) | Bio-responsive adhesive antibody delivery platform for immunotherapy and preparation method thereof | |
KR20230144960A (ko) | 신규 펩타이드 기반 면역항암제 | |
CA3208147A1 (en) | Methods and compounds for targeting cancer stem cells | |
Campeiro | Potential applications of the cell-penetrating peptide crotamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201110 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7234349 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |